Eisai, Meiji Seika's safinamide meets in Phase II/III for PD

Eisai Co. Ltd. (Tokyo:4523) and Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) reported preliminary data from a Phase II/III trial in about 410 Parkinson's disease patients

Read the full 263 word article

User Sign In